Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE publishes guidance on discounted Tarceva

This article was originally published in Scrip

Executive Summary

The UK's National Institute for health and Clinical Excellence(NICE) has published guidance that recommendsRoche's Tarceva (erlotinib) as an alternative toSanofi-Aventis's Taxotere (docetaxel) in treating non-small cell lung cancer patients who have failed on one chemotherapy regimen. The recommendation hinges on Roche's agreement with the department of health that the overall cost of treatment with Tarceva would be the same as using Taxotere, including the costs of administration, treating side-effects and monitoring. NICE does not recommend Tarceva as a second-line treatment for locally advanced or metastatic NSCLC in patients who are intolerant of Taxotere, for whom Taxotere is contraindicated, or for third-line treatment after Taxotere. The published guidance confirms the draft recommendations that NICE issued in July (Scrip Online, July 7th, 2008). Local healthcare authorities in England and Wales are expected to implement the guidance within three months.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts